Articles Tagged With: anticoagulation
-
Anticoagulated Trauma Patient
Emergency medicine providers commonly encounter anticoagulated trauma patients, and it is essential to understand the critical aspects of caring for this unique subpopulation, including specific traumatic injury patterns, emergent reversal, and surgical considerations, as well as relevant emerging concepts.
-
Timing of Anticoagulation Administration Following Atrial Fibrillation-Associated Stroke
A prospective, blinded, randomized study of early vs. later administration of oral anticoagulation after ischemic stroke in patients with atrial fibrillation calibrated by cerebral imaging showed no significant difference in 30-day outcomes.
-
Timing of Anticoagulation Administration Following Atrial Fibrillation-Associated Stroke
A prospective, blinded, randomized study of early vs. later administration of oral anticoagulation after ischemic stroke in patients with atrial fibrillation calibrated by cerebral imaging showed no significant difference in 30-day outcomes.
-
Reversal of Oral Anticoagulation in the Emergency Department
This review will describe the physiological components of the clotting cascade, highlight common anticoagulant agents in use, and discuss means of oral anticoagulation reversal.
-
Simplifying Anticoagulation: Apixaban for VTE in Patients with End-Stage Kidney Disease
There is a lower risk of bleeding with apixaban during the treatment of venous thromboembolism compared to warfarin in patients with end-stage kidney disease.
-
Oral Anticoagulation Falls Short as Default Treatment Post-TAVR
In patients without an indication for anticoagulation undergoing transcatheter aortic valve replacement, treatment with edoxaban did not significantly affect the incidence of leaflet thrombosis as detected by CT scans.
-
Intensive Monitoring for Asymptomatic Atrial Fibrillation Did Not Prevent Strokes
Screening with an implantable loop recorder resulted in dramatically higher rates of atrial fibrillation detection and ensuing anticoagulation, but without a significant decrease in risk of stroke or systemic embolism by six years of follow-up.
-
Pharmacotherapy for Atrial Fibrillation with Anticoagulation-Associated Intracranial Hemorrhage
A study of apixaban vs. no anticoagulation in patients following an anticoagulant for atrial fibrillation-related intracerebral hemorrhage exhibited a high risk of stroke and vascular death, regardless of whether the patients were treated subsequently with apixaban.
-
Intensive Monitoring for Asymptomatic Atrial Fibrillation Did Not Prevent Strokes
Screening with an implantable loop recorder resulted in dramatically higher rates of atrial fibrillation detection and ensuing anticoagulation, but without a significant decrease in risk of stroke or systemic embolism by six years of follow-up.
-
Is There a Role for Intermediate-Dose Anticoagulation for Critically Ill COVID-19 Patients?
In a multicenter, randomized clinical trial of critically ill COVID-19 patients, intermediate-dose compared to standard-dose prophylactic anticoagulation did not result in significant differences in the rates of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days.